Aviva PLC Blueprint Medicines Corp Transaction History

Aviva PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $435,126 - $885,373	-8,043 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$94.25 - $115.99 $910,172 - $1.12 Million	-9,657 Reduced 54.56%	8,043 $861,000
Q3 2021 Nov 12, 2021	BUY	$80.98 - $109.47 $1.43 Million - $1.94 Million	17,700 New	17,700 $1.82 Million
Q2 2021 Aug 10, 2021	SELL	$82.78 - $101.0 $1.04 Million - $1.27 Million	-12,566 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$90.71 - $108.28 $1.14 Million - $1.36 Million	12,566 New	12,566 $1.22 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.